These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28215131)

  • 1. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial.
    Chawla LS; Russell JA; Bagshaw SM; Shaw AD; Goldstein SL; Fink MP; Tidmarsh GF
    Crit Care Resusc; 2017 Mar; 19(1):43-49. PubMed ID: 28215131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
    Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial.
    Bokoch MP; Tran AT; Brinson EL; Marcus SG; Reddy M; Sun E; Roll GR; Pardo M; Fields S; Adelmann D; Kothari RP; Legrand M
    BMJ Open; 2023 Nov; 13(11):e078713. PubMed ID: 37984940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.
    Wieruszewski PM; Bellomo R; Busse LW; Ham KR; Zarbock A; Khanna AK; Deane AM; Ostermann M; Wunderink RG; Boldt DW; Kroll S; Greenfeld CR; Hodges T; Chow JH;
    Crit Care; 2023 May; 27(1):175. PubMed ID: 37147690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
    Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
    Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II for the Treatment of Vasodilatory Shock.
    Khanna A; English SW; Wang XS; Ham K; Tumlin J; Szerlip H; Busse LW; Altaweel L; Albertson TE; Mackey C; McCurdy MT; Boldt DW; Chock S; Young PJ; Krell K; Wunderink RG; Ostermann M; Murugan R; Gong MN; Panwar R; Hästbacka J; Favory R; Venkatesh B; Thompson BT; Bellomo R; Jensen J; Kroll S; Chawla LS; Tidmarsh GF; Deane AM;
    N Engl J Med; 2017 Aug; 377(5):419-430. PubMed ID: 28528561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial.
    Lamontagne F; Meade MO; Hébert PC; Asfar P; Lauzier F; Seely AJE; Day AG; Mehta S; Muscedere J; Bagshaw SM; Ferguson ND; Cook DJ; Kanji S; Turgeon AF; Herridge MS; Subramanian S; Lacroix J; Adhikari NKJ; Scales DC; Fox-Robichaud A; Skrobik Y; Whitlock RP; Green RS; Koo KKY; Tanguay T; Magder S; Heyland DK;
    Intensive Care Med; 2016 Apr; 42(4):542-550. PubMed ID: 26891677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multicenter Observational Cohort Study of Angiotensin II in Shock.
    Smith SE; Newsome AS; Guo Y; Hecht J; McCurdy MT; Mazzeffi MA; Chow JH; Kethireddy S
    J Intensive Care Med; 2022 Jan; 37(1):75-82. PubMed ID: 33231111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA): safety and efficacy of low-dose prostacyclin administration and blood pressure target in addition to standard therapy, as compared to standard therapy alone, in post-cardiac arrest syndrome patients: study protocol for a randomized controlled trial.
    Meyer AS; Ostrowski SR; Kjaergaard J; Johansson PI; Hassager C
    Trials; 2016 Aug; 17():378. PubMed ID: 27484224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.
    Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND
    Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent Hypotension.
    See EJ; Chaba A; Spano S; Maeda A; Clapham C; Burrell LM; Liu J; Khasin M; Liskaser G; Eastwood G; Bellomo R
    Crit Care Med; 2024 Aug; 52(8):1218-1227. PubMed ID: 38511994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study.
    Klijian A; Khanna AK; Reddy VS; Friedman B; Ortoleva J; Evans AS; Panwar R; Kroll S; Greenfeld CR; Chatterjee S
    J Cardiothorac Vasc Anesth; 2021 Jan; 35(1):51-58. PubMed ID: 32868152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Watson D; Grover R; Anzueto A; Lorente J; Smithies M; Bellomo R; Guntupalli K; Grossman S; Donaldson J; Le Gall JR;
    Crit Care Med; 2004 Jan; 32(1):13-20. PubMed ID: 14707555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
    Anstey MH; Wibrow B; Thevathasan T; Roberts B; Chhangani K; Ng PY; Levine A; DiBiasio A; Sarge T; Eikermann M
    BMC Anesthesiol; 2017 Mar; 17(1):47. PubMed ID: 28327122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of angiotensin II in treatment of refractory distributive shock.
    Rodriguez R; Fernandez EM
    Am J Health Syst Pharm; 2019 Jan; 76(2):101-107. PubMed ID: 31361800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II in septic shock.
    Jadhav AP; Sadaka FG
    Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial.
    Masse MH; Battista MC; Wilcox ME; Pinto R; Marinoff N; D'Aragon F; St-Arnaud C; Mayette M; Leclair MA; Quiroz Martinez H; Grondin-Beaudoin B; Poulin Y; Carbonneau É; Seely AJE; Watpool I; Porteous R; Chassé M; Lebrasseur M; Lauzier F; Turgeon AF; Bellemare D; Mehta S; Charbonney E; Belley-Côté É; Botton É; Cohen D; Lamontagne F; Adhikari NKJ; ;
    BMJ Open; 2020 Nov; 10(11):e037947. PubMed ID: 33191251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH).
    Gordon AC; Mason AJ; Perkins GD; Ashby D; Brett SJ
    BMJ Open; 2014 Jul; 4(7):e005866. PubMed ID: 24993769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ATHOS-3 trial, angiotensin II and The Three Musketeers.
    Bellomo R; Hilton A
    Crit Care Resusc; 2017 Mar; 19(1):3-4. PubMed ID: 28215124
    [No Abstract]   [Full Text] [Related]  

  • 20. Protocol adherence for continuously titrated interventions in randomized trials: an overview of the current methodology and case study.
    Lauzier F; Adhikari NK; Seely A; Koo KKY; Belley-Côté EP; Burns KEA; Cook DJ; D'Aragon F; Rochwerg B; Kho ME; Oczkowksi SJW; Duan EH; Meade MO; Day AG; Lamontagne F;
    BMC Med Res Methodol; 2017 Jul; 17(1):106. PubMed ID: 28716047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.